斑马鱼cetp基因敲除模型的建立及其肝脏转录组学分析

基础医学与临床 ›› 2020, Vol. 40 ›› Issue (7): 940-947.

斑马鱼cetp基因敲除模型的建立及其肝脏转录组学分析

冯冬萍^1,2, 商汉桥³, 杨航^3,4, 张虎军^3,4, 张停³, 杨梦溪², 屠强^3,4, 任景怡^1,2*

1.北京大学中日友好临床医学院, 北京 100029;
2.中日友好医院心内科,北京 100029;
3.中国科学院遗传与发育生物学研究所, 北京 100101;
4.中国科学院大学, 北京 100049

收稿日期:2020-05-08 修回日期:2020-05-15 出版日期:2020-07-05 发布日期:2020-06-29
通讯作者: ^*renjingyi1213@163.com
基金资助:
国家自然科学基金(81770359);中央保健科研课题(W2017BJ30);分子发育生物学国家重点实验室开放课题(2020-MDB-KF-17,2017-MDB-KF-13);中日友好医院青年基金(2017-1-QN-10)

Establishment of cetp^-/- model and liver transcriptomics study in zebrafish

FENG Dong-ping^1,2, SHANG Han-qiao³, YANG Hang^3,4, ZHANG Hu-jun^3,4, ZHANG Ting³, YANG Meng-xi², TU Qiang^3,4, REN Jing-yi^1,2*

1. Peking University China-Japan Friendship School of Clinical Medicine,Beijing 100029;
2. Department of Cardiology, China-Japan Friendship Hospital, Beijing 100029;
3. Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101;
4. University of Chinese Academy of Sciences, Beijing, 100049, China

Received:2020-05-08 Revised:2020-05-15 Online:2020-07-05 Published:2020-06-29
Contact: ^*renjingyi1213@163.com

摘要/Abstract

摘要： 目的建立斑马鱼cetp基因敲除模型,探讨cetp基因敲除后在动脉粥样硬化中的转录组学变化。方法采用CRISPR/Cas9基因编辑技术敲除斑马鱼cetp基因,构建cetp^-/-斑马鱼模型。采用转录组测序观察cetp基因敲除后基因表达谱变化,通过京都基因与基因组百科全书(KEGG)数据库对差异表达基因进行功能富集分析。结果采用CRISPR/Cas9技术敲除斑马鱼cetp基因,斑马鱼产生增加5个碱基的移码突变。转录组测序发现,cetp^-/-斑马鱼肝脏基因表达谱发生显著变化,共筛选到3 808个发生显著变化的基因(P＜0.05),其中显著上调基因有1 918个,显著下调基因1 890个。脂质代谢相关基因如abca1、abcg2a基因显著上调,lipg显著下调;与自噬相关信号通路基因如atg13显著上调;下调基因富集到DNA及RNA合成、三羧酸循环等相关通路。结论建立了斑马鱼cetp^-/-模型,可用于胆固醇酯转运蛋白(CETP)在动脉粥样硬化疾病中作用机制的研究。尽管抑制CETP可使高密度脂蛋白胆固醇升高而抑制动脉粥样硬化,但是斑马鱼cetp敲除后激活机体炎性反应而促进动脉粥样硬化,提示CETP在动脉粥样硬化发生发展的过程中具有双重调节作用。

关键词: 胆固醇酯转运蛋白, 动脉粥样硬化性心血管疾病, CRISPR/Cas9系统, 斑马鱼, 转录组测序

Abstract: Objective To investigate the transcriptomic changes in atherosclerosis after cetp knockout of zebrafish. Methods The gene editing technology CRISPR/Cas9 was used to knock out cetp of zebrafish to construct a homozygous mutant model. Total RNA of livers from wild type and cetp^-/- model was extracted by the Trizol method, and gene expression profiles of cetp knockout were observed by transcriptomics. KEGG enrichment analysis was performed on significantly different expressed genes to explore the signal pathways it may affect. Results Homozygous mutant zebrafish that has a frameshift mutation of adding 5 base pairs was created through CRISPR/Cas9 technology. Transcriptomics analysis showed that the gene expression profile of zebrafish liver changed significantly after cetp knockout. A total of 3 808 different expressed genes were screened (P＜0.05), of which 1 918 genes were up-regulated and 1 890 genes were down-regulated. Genes related to lipid metabolism such as abca1 and abcg2a were significantly up-regulated and lipg were significantly down-regulated. Genes related to autophagy signaling pathways such as atg13 were significantly up-regulated, and down-regulated genes were enriched in related pathways such as DNA and RNA synthesis and the tricarboxylic acid cycle. Conclusions A zebrafish model with cetp knockout is established to study the mechanism of cholesteryl ester transfer protein (CETP) in atherosclerotic diseases. Although increased high-density lipoprotein cholesterol due to the inhibition of CETP prevents atherosclero-sis, inflammation is activated after cetp knockout in zebrafish and causes atherosclerosis. It suggests that CETP has a dual regulation mechanism in the development of atherosclerosis.

Key words: cholesteryl ester transfer protein, atherosclerotic cardiovascular disease, CRISPR/Cas9 system, zebrafish, RNA-seq

中图分类号:

R541.4

冯冬萍, 商汉桥, 杨航, 张虎军, 张停, 杨梦溪, 屠强, 任景怡. 斑马鱼cetp基因敲除模型的建立及其肝脏转录组学分析[J]. 基础医学与临床, 2020, 40(7): 940-947.

FENG Dong-ping, SHANG Han-qiao, YANG Hang, ZHANG Hu-jun, ZHANG Ting, YANG Meng-xi, TU Qiang, REN Jing-yi. Establishment of cetp^-/- model and liver transcriptomics study in zebrafish[J]. Basic & Clinical Medicine, 2020, 40(7): 940-947.

参考文献

[1] World Health Organization. Cardiovascular diseases (CVDs) Fact Sheet[EB/OL] , 2017. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). Last accessed on 20 June 2018.
[2] Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial [J]. JAMA, 2005, 294: 2437-2445.
[3] LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease [J]. N Engl J Med, 2005, 352: 1425-1435.
[4] Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes [J]. N Engl J Med, 2004, 350: 1495-1504.
[5] Mabuchi H, Nohara A, Inazu A. Cholesteryl ester transfer protein (CETP) deficiency and CETP inhibitors [J]. Mol Cells, 2014, 37: 777-784.
[6] Barter PGA, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events [J]. N Engl J Med, 2007, 357: 1301-1310.
[7] Sheridan C. CETP inhibitors boost ‘good’ cholesterol to no avail [J]. Nat Biotechnol, 2016, 34: 5-6.
[8] Shrestha S, Wu BJ, Guiney L, et al. Cholesteryl ester transfer protein and its inhibitors [J]. J Lipid Res, 2018, 59: 772-783.
[9] Rohatgi A, Grundy SM. Cholesterol efflux capacity as a therapeutic target: rationale and clinical implications [J]. J Am Coll Cardiol, 2015, 66: 2211-2213.
[10] Tall AR, Rader DJ. Trials and tribulations of CETP inhibitors [J]. Circ Res, 2018, 122: 106-112.
[11] Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events [J]. N Engl J Med, 2007, 357: 2109-2122.
[12] Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome [J]. N Engl J Med, 2012, 367: 2089-2099.
[13] Lincoff AM, Nicholls SJ, Riesmeyer JS, et al. Evacetr-apib and cardiovascular outcomes in high-risk vascular disease [J]. N Engl J Med, 2017, 376: 1933-1942.
[14] Bowman L, Hopewell JC, Chen F, et al. Effects of anacetrapib in patients with atherosclerotic vascular disease [J]. N Engl J Med, 2017, 377: 1217-1227.
[15] Rosenson RS. The high-density lipoprotein puzzle: why classic epidemiology, genetic epidemiology, and clinical trials conflict? [J]. Arterioscler Thromb Vasc Biol, 2016, 36: 777-782.
[16] Barter PJ, Rye KA. Cholesteryl ester transfer protein inhibition is not yet dead—pro [J]. Arterioscler Thromb Vasc Biol, 2016, 36: 439-441.
[17] Quintao EC. The controversy over the use of cholesteryl ester transfer protein inhibitors: is there some light at the end of the tunnel? [J]. Eur J Clin Invest, 2016, 46: 581-589.
[18] Stoletov KFL, Choi SH, Hartvigsen K,et al. Vascular lipid accumulation, lipoprotein oxidation, and macrophage lipid uptake in hypercholesterolemic zebrafish [J]. Circ Res, 2009, 104: 952-960.
[19] Kimmel CB, Ballard WW, Kimmel SR, et al. Stages of embryonic development of the zebrafish [J]. Dev Dyn, 1995, 203: 253-310.
[20] Rosen JN, Sweeney MF, Mably JD. Microinjection of zebrafish embryos to analyze gene function [J]. J Vis Exp, 2009, 25: 1115.
[21] Porazinski SR, Wang H, Furutani-Seiki M. Microinjec-tion of medaka embryos for use as a model genetic organism [J]. J Vis Exp, 2010, 46: 1937.doi:10.3971/1937.
[22] Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association [J]. Circulation, 2017, 135: e146-e603.
[23] Colantonio LD, Bittner V, Reynolds K, et al. Association of serum lipids and coronary heart disease in contemporary observational studies [J]. Circulation, 2016, 133: 256-264.
[24] Inazu A, Brown ML, Hesler CB, et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation [J]. N Engl J Med 1990, 323: 1234-1238.
[25] Gut P, Reischauer S, Stainier DYR, et al. Little fish, big data: zebrafish as a model for cardiovascular and meta-bolic disease [J]. Physiol Rev, 2017, 97: 889-938.
[26] MacRae CA, Peterson RT. Zebrafish as tools for drug discovery [J]. Nat Rev Drug Discov, 2015, 14: 721-731.
[27] Schlegel A. Zebrafish models for dyslipidemia and atherosclerosis research [J]. Front Endocrinol(Lausanne), 2016, 7: 159.doi:10.3389/fendo.2016.00159.
[28] Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9 [J]. Science, 2014, 346: 1258096.doi:10.1126/science.1258096.
[29] Bochem AE, van Wijk DF, Holleboom AG, et al. ABCA1 mutation carriers with low high-density lipoprotein cholesterol are characterized by a larger atherosclerotic burden [J]. Eur Heart J, 2013, 34: 286-291.
[30] Ishida T, Choi S, Kundu RK, et al. Endothelial lipase is a major determinant of HDL level [J]. J Clin Invest, 2003, 111: 347-355.
[31] Edmondson AC, Brown RJ, Kathiresan S, et al. Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans [J]. J Clin Invest, 2009, 119: 1042-1050.
[32] Perrotta I. The use of electron microscopy for the detection of autophagy in human atherosclerosis [J]. Micron, 2013, 50: 7-13.
[33] Liu H, Cao Y, Tong T, et al. Autophagy in atherosclerosis: A phenomenon found in human carotid atherosclerotic plaques [J]. Chin Med J (Engl), 2015, 128: 69-74.
[34] Schrijvers DM, De Meyer GR, Martinet W. Autophagy in atherosclerosis: a potential drug target for plaque stabilization [J]. Arterioscler Thromb Vasc Biol, 2011, 31: 2787-2791.
[35] Ge Y, Huang M, Yao YM. Autophagy and proinflamma-tory cytokines: Interactions and clinical implications [J]. Cytokine Growth Factor Rev, 2018, 43: 38-46.
[36] Harris J. Autophagy and cytokines [J]. Cytokine, 2011, 56: 140-144.
[37] Ridker PM, Everett BM, Thuren T, et al. Antiinflamma-tory therapy with canakinumab for atherosclerotic disease [J]. N Engl J Med, 2017, 377: 1119-1131.